FTSE MIB
33.879,68 +250,47 (+0,74%) Dow Jones
38.829,33 +153,65 (+0,40%) Nasdaq
16.242,97 +86,64 (+0,54%) Nikkei 225
38.236,07 -38,03 (-0,10%) Petrolio
78,60 +0,49 (+0,63%) Bitcoin EUR
59.320,88 -67,39 (-0,11%)
CERE May 2024 20.000 put
| Chiusura precedente | 0,1500 |
| Aperto | 0,1500 |
| Denaro | 0,0000 |
| Lettera | 4,8000 |
| Prezzo d'esercizio | 20,00 |
| Scadenza | 2024-05-17 |
| Min-Max giorno | 0,1500 - 0,1500 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 12 |
GlobeNewswireCerevel Therapeutics to Report Third Quarter 2023 Financial Results and Business Updates on Wednesday, November 1, 2023
CAMBRIDGE, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report third quarter 2023 financial results and business updates on Wednesday, November 1, 2023, before the U.S. financial markets open. Management will host a conference call to discuss third quarter financial results and business updates on Wednesday, November 1 at 8:00 a.m. ET. To access th
- GlobeNewswire
Cerevel Therapeutics Announces Pricing of $450 Million Public Offering of Common Stock
CAMBRIDGE, Mass., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics Holdings, Inc. (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today the pricing of its previously announced underwritten public offering of 19,728,189 shares of its common stock at a public offering price of $22.81 per share, or approximately $450 million of shares of its common stock. In addition, Cerevel granted the underwriters a 30-day option to pur
- GlobeNewswire
Cerevel Therapeutics Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics Holdings, Inc. (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today that it has commenced an underwritten public offering of $400.0 million of shares of its common stock. In connection with this offering, Cerevel expects to grant the underwriters a 30-day option to purchase up to an additional $60.0 million of shares of its common stock at the public of
